{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:38:58.099370+00:00","company":{"ticker":"RNTX","cik":1420565,"company_name":"Rein Therapeutics, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"075a3b170dc8b75c1501f3553679aba8e86c1b42","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Konik Capital Partners, LLC","effective_date":"2026-04-30","item_codes_triggered":["1.01"],"value_text":"$1.00 per share, before underwriting discounts and commissions"},"claim":"Rein Therapeutics, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC valued at $1.00 per share, before underwriting discounts and commissions (effective 2026-04-30).","evidence_excerpt":"On April 30, 2026, Rein Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, acting as sole book-running manager, relating to the issuance and sale of 50,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-204006","anchor_url":"https://secwatch.observer/filing/0001193125-26-204006#claim-075a3b170dc8b75c1501f3553679aba8e86c1b42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/0001193125-26-204006-index.htm"},{"fact_type":"debt_financing","fact_key":"122dd453942f7d521d74bbd9ad15b9e204bbd690","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"counterparty":"three institutional investors","effective_date":"2026-02-24","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"20% original issue discount","item_codes_triggered":["2.03"],"maturity_text":"the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions","principal_text":"$2,875,000"},"claim":"Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.","evidence_excerpt":"On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-084012","anchor_url":"https://secwatch.observer/filing/0001193125-26-084012#claim-122dd453942f7d521d74bbd9ad15b9e204bbd690","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm"},{"fact_type":"material_agreement","fact_key":"1d9bcbb6366c1040c55605929a4c4f8512de5c10","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"notes_offering","counterparty":"three institutional investors","effective_date":null,"item_codes_triggered":["1.01"],"value_text":"$2,875,000"},"claim":"Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.","evidence_excerpt":"On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-084012","anchor_url":"https://secwatch.observer/filing/0001193125-26-084012#claim-1d9bcbb6366c1040c55605929a4c4f8512de5c10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm"},{"fact_type":"material_agreement","fact_key":"baa51a2e86fdee7704273b6edb9de1e90add4553","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2026-01-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Funicular Funds, LP","effective_date":"2026-01-15","item_codes_triggered":["1.01"],"value_text":"original principal amount of $2,500,000"},"claim":"Rein Therapeutics, Inc. entered into Purchase Agreement with Funicular Funds, LP valued at original principal amount of $2,500,000 (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, Rein Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Funicular Funds, LP, a Delaware limited partnership managed by Cable Car Capital, LP (“Funicular”), pursuant to which the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-015524","anchor_url":"https://secwatch.observer/filing/0001193125-26-015524#claim-baa51a2e86fdee7704273b6edb9de1e90add4553","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526015524/0001193125-26-015524-index.htm"},{"fact_type":"debt_financing","fact_key":"4ca8e4b6c6c975a2d89ad24cbd25a809e579c4df","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2026-01-16T23:59:59+00:00","payload":{"counterparty":"Funicular Funds, LP","effective_date":"2026-01-15","event":"incurrence","instrument_type":"loan","interest_rate_text":"20% original issue discount","item_codes_triggered":["2.03"],"maturity_text":"the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions","principal_text":"$2,500,000"},"claim":"Rein Therapeutics, Inc. incurred loan of $2,500,000 with Funicular Funds, LP at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.","evidence_excerpt":"the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-015524","anchor_url":"https://secwatch.observer/filing/0001193125-26-015524#claim-4ca8e4b6c6c975a2d89ad24cbd25a809e579c4df","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526015524/0001193125-26-015524-index.htm"},{"fact_type":"debt_financing","fact_key":"b06c4b99960891a0854f7a43045cfe0963e2846b","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-10-24T23:59:59+00:00","payload":{"counterparty":"YA II PN, Ltd.","effective_date":"2025-10-23","event":"incurrence","instrument_type":"other","interest_rate_text":"8%","item_codes_triggered":["2.03"],"maturity_text":"12-month anniversary of their issuance","principal_text":"$1.0 million"},"claim":"Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8% maturing 12-month anniversary of their issuance.","evidence_excerpt":"(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-250175","anchor_url":"https://secwatch.observer/filing/0001193125-25-250175#claim-b06c4b99960891a0854f7a43045cfe0963e2846b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525250175/0001193125-25-250175-index.htm"},{"fact_type":"debt_financing","fact_key":"576823e8e3c318ea749b34c523ab37edd9fb5547","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-09-09T23:59:59+00:00","payload":{"counterparty":"YA II PN, Ltd.","effective_date":"2025-09-08","event":"incurrence","instrument_type":"other","interest_rate_text":"8%","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$1.0 million"},"claim":"Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8%.","evidence_excerpt":"(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-198816","anchor_url":"https://secwatch.observer/filing/0001193125-25-198816#claim-576823e8e3c318ea749b34c523ab37edd9fb5547","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525198816/0001193125-25-198816-index.htm"},{"fact_type":"debt_financing","fact_key":"9a03ede5289f522ad48a1d6b94aef46fd04538bf","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-07-30T23:59:59+00:00","payload":{"counterparty":"YA II PN, Ltd.","effective_date":"2025-07-29","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"8%","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"up to $6.0 million"},"claim":"Rein Therapeutics, Inc. incurred credit facility of up to $6.0 million with YA II PN, Ltd. at 8%.","evidence_excerpt":"(the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, the Company may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-168830","anchor_url":"https://secwatch.observer/filing/0001193125-25-168830#claim-9a03ede5289f522ad48a1d6b94aef46fd04538bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525168830/0001193125-25-168830-index.htm"},{"fact_type":"governance_change","fact_key":"76f5ac5d644e300585472eaac022c8204332354d","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-07-11T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-07-10","item_codes_triggered":["5.03"],"summary_text":"Amended quorum requirement to 40% of outstanding shares entitled to vote at stockholder meetings"},"claim":"Rein Therapeutics, Inc.: Amended quorum requirement to 40% of outstanding shares entitled to vote at stockholder meetings (effective 2025-07-10).","evidence_excerpt":"On July 10, 2025, the Board of Directors (the “Board”) of Rein Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated By-laws (as amended, the “By-laws”), effective immediately, to provide that forty percent (40%) of the shares of capital stock of the Company issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law, the Restated Certificate of Incorporation, as amended, or the By-laws.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-158192","anchor_url":"https://secwatch.observer/filing/0001193125-25-158192#claim-76f5ac5d644e300585472eaac022c8204332354d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/0001193125-25-158192-index.htm"},{"fact_type":"executive_change","fact_key":"5e4383b4ea","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-16","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-140688","anchor_url":"https://secwatch.observer/filing/0001193125-24-140688#claim-5e4383b4ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm"},{"fact_type":"executive_change","fact_key":"82bd67ca6e","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Timothy M. Cunningham","successor_named":true},"claim":"Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"Mr. Garner's departure from the Company on May 15, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-140688","anchor_url":"https://secwatch.observer/filing/0001193125-24-140688#claim-82bd67ca6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm"},{"fact_type":"earnings_release","fact_key":"18627591e3d403767a584cc609240d6d85620c64","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-139510","anchor_url":"https://secwatch.observer/filing/0001193125-24-139510#claim-18627591e3d403767a584cc609240d6d85620c64","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm"},{"fact_type":"material_agreement","fact_key":"023ed1d2483c38509012478c2a03d3ed32b8f991","cik":1420565,"ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Titan Partners Group LLC, a division of American Capital Partners, LLC","effective_date":"2024-05-01","item_codes_triggered":["1.01"],"value_text":"combined offering price of $4.68"},"claim":"Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).","evidence_excerpt":"On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-127657","anchor_url":"https://secwatch.observer/filing/0001193125-24-127657#claim-023ed1d2483c38509012478c2a03d3ed32b8f991","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm"}]}